Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody
Hector Quijada, Tadeo Bermudez, Carrie L. Kempf, Daniel G. Valera, Alexander N. Garcia, Sara M. Camp, Jin H. Song, Evelyn Franco, Jessica K. Burt, Belinda Sun, Joseph B. Mascarenhas, Kimberlie Burns, Amir Gaber, Radu C. Oita, Vivian Reyes Hernon, Christy Barber, Liliana Moreno-Vinasco, Xiaoguang Sun, Anne E. Cress, Diego Martin, Zhonglin Liu, Ankit A. Desai, Viswanathan Natarajan, Jeffrey R. Jacobson, Steven M. Dudek, Christian Bime, Saad Sammani, Joe G.N. Garcia
Source: Eur Respir J, 57 (5) 2002536; 10.1183/13993003.02536-2020
Abstract
Rationale
The severe acute respiratory syndrome coronavirus 2/coronavirus disease 2019 pandemic has highlighted the serious unmet need for effective therapies that reduce acute respiratory distress syndrome (ARDS) mortality. We explored whether extracellular nicotinamide phosphoribosyltransferase (eNAMPT), a ligand for Toll-like receptor (TLR)4 and a master regulator of innate immunity and inflammation, is a potential ARDS therapeutic target.
Methods
Wild-type C57BL/6J or endothelial cell (EC)-cNAMPT -/- knockout mice (targeted EC NAMPT deletion) were exposed to either a lipopolysaccharide (LPS)-induced (“one-hit”) or a combined LPS/ventilator (“two-hit”)-induced acute inflammatory lung injury model. A NAMPT-specific monoclonal antibody (mAb) imaging probe (99m Tc-ProNamptor) was used to detect NAMPT expression in lung tissues. Either an eNAMPT-neutralising goat polyclonal antibody (pAb) or a humanised monoclonal antibody (ALT-100 mAb) were used in vitro and in vivo .
Results
Immunohistochemical, biochemical and imaging studies validated time-dependent increases in NAMPT lung tissue expression in both pre-clinical ARDS models. Intravenous delivery of either eNAMPT-neutralising pAb or mAb significantly attenuated inflammatory lung injury (haematoxylin and eosin staining, bronchoalveolar lavage (BAL) protein, BAL polymorphonuclear cells, plasma interleukin-6) in both pre-clinical models. In vitro human lung EC studies demonstrated eNAMPT-neutralising antibodies (pAb, mAb) to strongly abrogate eNAMPT-induced TLR4 pathway activation and EC barrier disruption. In vivo studies in wild-type and EC-cNAMPT -/- mice confirmed a highly significant contribution of EC-derived NAMPT to the severity of inflammatory lung injury in both pre-clinical ARDS models.
Conclusions
These findings highlight both the role of EC-derived eNAMPT and the potential for biologic targeting of the eNAMPT/TLR4 inflammatory pathway. In combination with predictive eNAMPT biomarker and NAMPT genotyping assays, this offers the opportunity to identify high-risk ARDS subjects for delivery of personalised medicine.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hector Quijada, Tadeo Bermudez, Carrie L. Kempf, Daniel G. Valera, Alexander N. Garcia, Sara M. Camp, Jin H. Song, Evelyn Franco, Jessica K. Burt, Belinda Sun, Joseph B. Mascarenhas, Kimberlie Burns, Amir Gaber, Radu C. Oita, Vivian Reyes Hernon, Christy Barber, Liliana Moreno-Vinasco, Xiaoguang Sun, Anne E. Cress, Diego Martin, Zhonglin Liu, Ankit A. Desai, Viswanathan Natarajan, Jeffrey R. Jacobson, Steven M. Dudek, Christian Bime, Saad Sammani, Joe G.N. Garcia. Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody. Eur Respir J, 57 (5) 2002536; 10.1183/13993003.02536-2020
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Dual inhibition of Angiopoietin-2 and VEGF-A with a monoclonal antibody improves pulmonary capillary leakage in murine experimental sepsis Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure Year: 2019
Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019 Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011
Anti-CTGF antibody attenuates silica-induced lung fibrosis in rats Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis Source: Eur Respir J 2016; 47:1481-1491 Year: 2016
Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
Kallistatin protects against LPS-induced mouse lung injury Source: Annual Congress 2012 - The many roads to lung injury Year: 2012
LATE-BREAKING ABSTRACT: Phase 2 trial of FG-3019, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): Preliminary safety and efficacy results Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012
Immunotherapy improves inflammatory response and lymphocyte apoptosis as a new therapeutic target in sepsis rat Source: Annual Congress 2009 - Severe sepsis and multiple organ failure Year: 2009
Preclinical development of an IL-13 neutralising antibody, CAT-354, for the treatment of human asthma Source: Eur Respir J 2005; 26: Suppl. 49, 367s Year: 2005
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Inflammation and remodeling modulated by anti IL17 in model of lung injury induced by elastase in mice Source: International Congress 2019 – Involvement of the environment and inflammation in pulmonary remodelling Year: 2019
Dipeptide HCH6-1 inhibits neutrophil activation and protects against acute lung injury by blocking FPR1 Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
PBI-compound, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen production in murine and human fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013
Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Enhanced expression of Robo4 ameliorates LPS-induced acute lung injury in mice Source: Annual Congress 2011 - Acute respiratory failure Year: 2011
CD101 eosinophil serves as an early response to suppress endotoxin-induced acute lung injury Source: International Congress 2018 – Role of microbial exposure and inflammation in lung injury Year: 2018
Effects of autophagy on LPS-induced lung inflammation and acute lung injury (ALI) in vitro and in vivo Source: International Congress 2018 – Role of microbial exposure and inflammation in lung injury Year: 2018
Sustained PAP-reduction and tissue cGMP-restoration without systemic NO-generation by aerosolized PAPA-NONOate in an isolated lung model of acute lung injury Source: Eur Respir J 2004; 24: Suppl. 48, 561s Year: 2004
Pioglitazone attenuates endotoxin-induced acute lung injury by reducing neutrophil recruitment Source: Eur Respir J 2012; 40: 416-423 Year: 2012
Effects of N-acetylcysteine in lipopolysaccharide-induced acute lung injury in the rat: Treatment after acute lung injury Source: Annual Congress 2011 - Mechanical ventilation and lung injury: new advances Year: 2011